Brazil OTC drug maker Aeroflex ignored FDA records requests, prompting possible approval holds and US shipment refusals.
What happened
FDA says Aeroflex is registered as an OTC drug manufacturer, and previous correspondence indicated it makes and imports multiple drug products; one product is sold on online marketplaces. On October 27, 2025, FDA emailed a request for records and other information under section 704(a)(4) to the registration contact, and the request and numerous follow-ups went unanswered. FDA says it therefore has no indication of the quality assurance level for drugs listed as manufactured at the facility.
What FDA found
The company did not answer FDA's electronic request for records and other information about its drug manufacturing.
section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))Refusing to permit access to or copying of required records is a prohibited act.
section 301(e) of the FD&C Act (21 U.S.C. 331(e))The company also did not answer numerous follow-up requests from FDA.
What FDA wants
Within 15 working days, respond in writing to confirm or update the company's registration and/or drug listing status and say whether it will answer the records request. If Aeroflex no longer makes drugs, FDA asks it to delist all previously listed drugs using the last lot expiration date as the marketing end date and deregister the facility.
Who should pay attention
- US importers and distributors of Aeroflex OTC drugs
- brands and online sellers sourcing products made by this facility
- companies listing Aeroflex as a drug manufacturer in FDA applications
This is a summary. Read the original letter on fda.gov.